

## Instructions for Authors 2016

*General Policy.* ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

*Tables.* All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

*References.* Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Ethical Policies and Standards.* ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

*Submission of Manuscripts.* Please follow the Instructions for Authors regarding the format of your manuscript and references.

Manuscripts must be submitted only through our online submission system at: <http://www.iiar-submissions.com/login.html>

In case a submission is incomplete, the corresponding Author will be notified accordingly.

Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles published in 2015 are entitled to a complimentary online subscription to Anticancer Research 2015. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Copyright© 2016 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

### ***Specific information and additional instructions for Authors***

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees. (For further information please click [here](#))
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
  - The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
  - Results given in figures should not be repeated in tables.
  - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
  - they do not fall within the journal's policy.
  - they do not follow the instructions to authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to AR.
  - plagiarism is detected by plagiarism screening services.

(Rejection rate (2015): 64%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

False-negative Frozen Section of Sentinel Lymph Node Biopsy in a Chinese Population with Breast Cancer. G. QIAO, Y. CONG, H. ZOU, J. LIN, X. WANG, X. LI, Y. LI, S. ZHU ( <i>Yantai, Shandong, PR China</i> ) .....	1331
<b>PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM “BIOLOGIC EFFECTS OF LIGHT” (Homburg/Saar, Germany) .....</b>	<b>1339-1444</b>
Biologic Effects of Light: An Enlightening Prospective. J. REICHRATH, K. BERG, S. EMMERT, J. LADEMANN, G. SECKMEYER, L. ZASTROW, T. VOGT, M.F. HOLICK ( <i>Homburg; Rostock; Berlin; Hannover, Germany; Oslo, Norway; Boston, MA, USA</i> ) .....	1339
Biological Effects of Sunlight, Ultraviolet Radiation, Visible Light, Infrared Radiation and Vitamin D for Health. M.F. HOLICK ( <i>Boston, MA, USA</i> ) .....	1345
Review: Roles of Solar UVB and Vitamin D in Reducing Cancer Risk and Increasing Survival. W.B. GRANT ( <i>San Francisco, CA, USA</i> ) .....	1357
Review: Photocarcinogenesis and Skin Cancer Prevention Strategies. C. SEEBODE, J. LEHMANN, S. EMMERT ( <i>Rostock; Goettingen, Germany</i> ) .....	1371
Review: Vitamin D and Mortality. S. PILZ, M. GRÜBLER, M. GAKSCH, V. SCHWETZ, C. TRUMMER, B.Ó. HARTAIGH, N. VERHEYEN, A. TOMASCHITZ, W. MÄRZ ( <i>Graz; Bad Aussee, Austria; Amsterdam, the Netherlands; Bern, Switzerland; New York, NY; New Haven, CT, USA; Mannheim, Germany</i> ) .....	1379
Short Review: Light - Instead of UV Protection: New Requirements for Skin Cancer Prevention. L. ZASTROW, J. LADEMANN ( <i>Berlin, Germany</i> ) .....	1389
Short Review: Extracorporeal Photopheresis for Non-skin GvHD. J. BITTENBRING, J. REICHRATH ( <i>Homburg, Germany</i> ) .....	1395
Vitamin D Status in Chronic Kidney Disease – UVB Irradiation Is Superior to Oral Supplementation. R. KRAUSE, H.J. ROTH, H. KAASE, R. STANGE, M.F. HOLICK ( <i>Berlin; Heidelberg, Germany; Boston, MA, USA</i> ) .....	1397
UV Irradiation and Pleiotropic Effects of Vitamin D in Chronic Kidney Disease – Benefits on Cardiovascular Comorbidities and Quality of Life. R. KRAUSE, R. STANGE, H. KAASE, M.F. HOLICK ( <i>Berlin, Germany; Boston, MA, USA</i> ) .....	1403
Layer Thickness of SPF 30 Sunscreen and Formation of Pre-vitamin D. M. GRIGALAVICIUS, V. IANI, A. JUZENIENE ( <i>Oslo, Norway</i> ) .....	1409
Optimization of Chemical Syntheses of Vitamin D C3-Epimers. L. KATTNER, E. RAUCH ( <i>Saarbrücken, Germany</i> ) .....	1417
Solar Simulators for Healthy Vitamin D Synthesis. G. SECKMEYER, M. SCHREMPF, A. STÜHRMANN, A. NIEDZWIEDZ ( <i>Hannover, Germany</i> ) .....	1423
Human Pigmentation, Cutaneous Vitamin D Synthesis and Evolution: Variants of Genes (SNPs) Involved in Skin Pigmentation Are Associated with 25(OH)D Serum Concentration. W. ROSSBERG, R. SATERNUS, S. WAGENPFEIL, M. KLEBER, W. MÄRZ, S. REICHRATH, T. VOGT, J. REICHRATH ( <i>Homburg; Mannheim; Augsburg, Germany; Graz, Austria</i> ) .....	1429
Prospective Investigation of 25(OH)D <sub>3</sub> Serum Concentration Following UVB Narrow Band Phototherapy in Patients with Psoriasis and Atopic Dermatitis. A. WEINHOLD, R. OBEID, T. VOGT, J. REICHRATH ( <i>Homburg, Germany</i> ) .....	1439
Errata .....	1445

Microwave Ablation: The Differences Between Biliary Cirrhosis and Normal Porcine Liver Using a Cooled-tip Electrode. L.-G. WANG, W.-J. JIANG, W.-J. FAN, Y.-B. ZHENG, X.-P. SONG, S. LIU, B.-L. SUN, T. WANG ( <i>Yantai, Shandong; Guangzhou, Guangdong, PR China</i> ) .....	1221
Prostate Apoptosis Response-4 (PAR4) Suppresses Growth and Invasion of Breast Cancer Cells and Is Positively Associated with Patient Survival. L.K. SATHERLEY, P.-H. SUN, K. JI, M. MASON, R. HARGEST, W.G. JIANG, L. YE ( <i>Cardiff, UK</i> ) .....	1227
The Impact of TIMM17A on Aggressiveness of Human Breast Cancer Cells. X. YANG, Y. SI, T. TAO, T.A. MARTIN, S. CHENG, H. YU, J. LI, J. HE, W.G. JIANG ( <i>Beijing, PR China; Cardiff, UK</i> ) .....	1237
Relationship Between HSP70 and ERBB2 Expression in Breast Cancer Cell Lines Regarding Drug Resistance. L. YUE, J.-Y. XIANG, P. SUN, Y.-S. YAO, Z.-N. SUN, X.-P. LIU, H.-B. WANG, Z. SHEN, R.-Y. YAO ( <i>Qingdao; Yantai; Shanghai, PR China</i> ) .....	1243
ADAM29 Expression in Human Breast Cancer and its Effects on Breast Cancer Cells <i>In Vitro</i> . M. ZHAO, W. JIA, W.G. JIANG, P. WANG, G. DU, S. CHENG, M. SONG ( <i>Beijing, PR China; Cardiff, UK</i> ) .....	1251
Possible Effect of Muscle-relaxant Anaesthetics on Invasion, Adhesion and Migration of Breast Cancer Cells. A. JIANG, H. ZHAO, J. CAI, W.G. JIANG ( <i>Yantai; Beijing, PR China; Cardiff, UK</i> ).....	1259
The Clinical Implications of RSK1-3 in Human Breast Cancer. H. ZHAO, T.A. MARTIN, E.L. DAVIES, F. RUGE, H. YU, Y. ZHANG, X. TENG, W.G. JIANG ( <i>Cardiff, UK; Beijing, PR China</i> ).....	1267
Expression of PIN1 in Gastrointestinal Stromal Tumours and its Clinical Significance. L. JIANG, M. CAO, J. HU, J. CHEN ( <i>Yantai, Shandong Province, PR China</i> ) .....	1275
Expression of Semaphorin 3C in Breast Cancer and its Impact on Adhesion and Invasion of Breast Cancer Cells. M.F.A. MALIK, L.K. SATHERLEY, E.L. DAVIES, L. YE, W.G. JIANG ( <i>Cardiff, UK; Islamabad, Pakistan</i> ) .....	1281
Metastasis to Bone in Human Cancer Is Associated with Loss of Occludin Expression. T.A. MARTIN, N. JORDAN, E.L. DAVIES, W.G. JIANG ( <i>Cardiff, UK</i> ) .....	1287
Reduced RanBPM Expression Is Associated with Distant Metastasis in Gastric Cancer and Chemoresistance. S. SHAO, P.-H. SUN, L.K. SATHERLEY, X. GAO, K. JI, Y. FENG, Y. JIA, J. JI, W.G. JIANG, L. YE ( <i>Cardiff, UK; Beijing, PR China</i> ) .....	1295
<i>Clinical Studies</i>	
The Effects of Different Methods of Anaesthesia for Laparoscopic Radical Gastrectomy with Monitoring of Entropy. A. JIANG, L.-J. CHEN, Y.-X. WANG, M.-C. LI, Y.-B. DING ( <i>Yantai, Shandong Province, PR China</i> ) .....	1305
Hypocalcaemia After Total Knee Arthroplasty and its Clinical Significance. P. GAI, H. SUN, L. SUI, G. WANG ( <i>Yantai, Shandong Province, PR China</i> ) .....	1309
Effective Treatment for Malignant Pleural Effusion and Ascites with Combined Therapy of Bevacizumab and Cisplatin. L. JIANG, P. LI, Z. GONG, B. HU, J. MA, J. WANG, H. CHU, L. ZHANG, P. SUN, J. CHEN ( <i>Yantai, Shandong, PR China</i> ) .....	1313
Partial Resection of the Pancreatic Head and Duodenum for Management of Carcinoma of the Ampulla of Vater: A Case Report. X.-F. LIU, K. TANG, F.-B. SUN, L.-L. SUI, G. XU ( <i>Yantai, PR China</i> ) .....	1319
Endoscopic Resection of Giant Ethmoid Osteomas with the Assistance of an Image-guidance System. Y. WANG, D. LI, A. JIANG, H. ZHANG, Y. SUN, Z. LIU, X. SONG ( <i>Yantai, PR China</i> ) .....	1325



Locked Nucleic Acid <i>In Situ</i> Hybridization Analysis of MicroRNA-21 Predicts Clinical Outcome in Patients After Resection for Pancreatic Cancer Treated with Adjuvant Gemcitabine Monotherapy. S. MORINAGA, Y. NAKAMURA, Y. ATSUMI, M. MURAKAWA, K. YAMAOKU, T. AOYAMA, S. KOBAYASHI, M. UENO, M. MORIMOTO, T. YOKOSE, Y. MIYAGI ( <i>Yokohama, Japan</i> ) .....	1083
Impact of the Radiation Dose on Survival after Radiochemotherapy for Small-cell Lung Cancer. L. KÄSMANN, S. JANSSEN, S.E. SCHILD, D. RADES ( <i>Lübeck; Hannover, Germany; Scottsdale, AZ, USA</i> ).....	1089
<b>PROCEEDINGS OF THE CHINA –UNITED KINGDOM CANCER (CUKC) CONFERENCE 2015</b> <b>(Cardiff, Wales, UK) .....</b>	1093-1338
<i>Reviews</i>	
Biomarkers in Colorectal Cancer. A.J. YIU, C.Y. YIU ( <i>London, UK</i> ) .....	1093
Phosphoinositide-3-Kinase Enhancers, PIKES: Their Biological Functions and Roles in Cancer. W. JIA, Y. FENG, A.J. SANDERS, E.L. DAVIES, W.G. JIANG ( <i>Cardiff, UK; Guangzhou, PR China</i> ).....	1103
Update on Biomarkers in Development of Anti-angiogenic Drugs in Gastric Cancer. S. JIA, J. CAI ( <i>Cardiff, UK; Beijing, PR China</i> ) .....	1111
Tumour–Endothelial Cell Communications: Important and Indispensable Mediators of Tumour Angiogenesis. B.M. LOPES-BASTOS, W.G. JIANG, J. CAI ( <i>Cardiff, UK</i> ) .....	1119
<i>Experimental Studies</i>	
Targeting of Receptor Activator of Nuclear Kappa B (RANK) in PC-3 Cells Increases Cell Proliferation and Matrix Adhesion <i>In Vitro</i> . S. OWEN, A.J. SANDERS, M.D. MASON, W.G. JIANG ( <i>Cardiff, UK</i> ) .....	1127
The Association Between WAVE1 and -3 and the ARP2/3 Complex in PC 3 Cells. H.P. WEEKS, A.J. SANDERS, H.G. KYNASTON, W.G. JIANG ( <i>Cardiff, UK</i> ) .....	1135
MDM2 and PSMA Play Inhibitory Roles in Metastatic Breast Cancer Cells Through Regulation of Matrix Metalloproteinases. R. BRADBURY, W.G. JIANG, Y.-X. CUI ( <i>Cardiff, UK</i> ) .....	1143
IL24 and its Receptors Regulate Growth and Migration of Pancreatic Cancer Cells and Are Potential Biomarkers for IL24 Molecular Therapy. Y. JIA, K. JI, J. JI, C. HAO, L. YE, A.J. SANDERS, W.G. JIANG ( <i>Cardiff, UK; Beijing, PR China</i> ) .....	1153
A Novel <i>NHERF1</i> Mutation in Human Breast Cancer Inactivates Inhibition by NHERF1 Protein in EGFR Signaling. G. DU, C. HAO, Y. GU, Z. WANG, W.G. JIANG, J. HE, S. CHENG ( <i>Beijing, PR China; Cardiff, UK</i> ).....	1165
Biochemical Features of Recombinant Human Cyclophilin J. J. CHEN, R. LIEFKE, L. JIANG, J. WANG, C. HUANG, Z. GONG, C. SCHIENE-FISCHER, L. YU ( <i>Shandong; Shanghai, P.R. China; Halle/Saale, Germany</i> ) .....	1175
Effect of YangZheng XiaoJi Extract, DME-25, on Endothelial Cells and their Response to Avastin. S. OWEN, Y. GAO, X. ZHI, C. WEI, Y. WU, W.G. JIANG ( <i>Cardiff, UK; Beijing; Shijiazhuang, HeBei, PR China</i> ) .....	1181
New Roles of Osteocytes in Proliferation, Migration and Invasion of Breast and Prostate Cancer Cells. Y.-X. CUI, B.A.J. EVANS, W.G. JIANG ( <i>Cardiff, UK</i> ) .....	1193
Discovery of a Regulatory Motif for Human Satellite DNA Transcription in Response to <i>BATF2</i> Overexpression. X. BAI, W. HUANG, C. ZHANG, J. NIU, W. DING ( <i>Beijing, PR China</i> ) .....	1203
Knockdown of <i>EPHA1</i> by CRISPR/CAS9 Promotes Adhesion and Motility of HRT18 Colorectal Carcinoma Cells. B. WU, W.G. JIANG, D. ZHOU, Y.-X. CUI ( <i>Beijing, PR China; Cardiff, UK</i> ) .....	1211

Phase I Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Local or Metastatic Esophageal Cancer. K. IWASAKI, Y. OSAKA, S. TACHIBANA, T. SUDA, Y. OTA, S. HOSHINO, A. TSUCHIDA ( <i>Tokyo, Japan</i> ) .....	987
Prognostic Significance of the Preoperative Ratio of C-Reactive Protein to Albumin in Patients with Colorectal Cancer. M. SHIBUTANI, K. MAEDA, H. NAGAHARA, Y. ISEKI, T. IKEYA, K. HIRAKAWA ( <i>Osaka, Japan</i> ).....	995
Neuroendocrine Neoplasms of the Ovary: A Retrospective Study of the North Eastern German Society of Gynecologic Oncology (NOGGO). J. SEHOULI, H. WOOPEN, M. PAVEL, R. RICHTER, L.-K. LAUTERBACH, E. TAUBE, S. DARB-ESFAHANI, C. FOTOPOULOU, K. PIETZNER ( <i>Berlin, Germany; London, UK</i> ) .....	1003
Postmyomectomy Uterine Rupture Despite Cesarean Section. J. KACPERCZYK, P. BARTNIK, E. ROMEJKO-WOLNIEWICZ, A. DOBROWOLSKA-REDO ( <i>Warsaw, Poland</i> ).....	1011
Role of IGF-I in Primary Ovarian Cancer – A Study of the OVCAD European Consortium. I. ROHR, R. ZEILLINGER, M. HEINRICH, N. CONCIN, I. VERGOTE, M. NASSIR, S. MAHNER, E. VAN NIEUWENHUYSEN, F. TRILLSCH, D. CACSIRE-TONG, R. CHEKEROV, J. SEHOULI, E.I. BRAICU ( <i>Berlin; Hamburg, Germany; Vienna; Innsbruck, Austria; Leuven, Belgium</i> ) .....	1015
Results of Further Diagnostic Procedures Among Patients with Cytological Characteristics of Minor Changes on Pap Smears. J. KACPERCZYK, P. BARTNIK, E. ROMEJKO-WOLNIEWICZ, K. JALINIK ( <i>Warsaw, Poland</i> ) .....	1023
Effect of Denosumab Administration on Lumbar Vertebral Strength of Patients with Vertebral Bony Metastases: Preliminary Study. K. KAWANAMI, N. WAKAO, K. MUROTANI, M. KAMIYA, M. TAKEUCHI, A. HIRASAWA, T. MATSUO, K. SATO, M. DEIE ( <i>Nagakute, Aichi, Japan</i> ) .....	1027
Clinical Outcomes of Patients with Extensive Peritoneal Carcinomatosis Following Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy. Y. HUANG, N.A. ALZAHIRANI, T.C. CHUA, Y.R. HUO, D.L. MORRIS ( <i>Sydney; St Leonards, NSW, Australia; Riyadh, Kingdom of Saudi Arabia</i> ) .....	1033
Prognostic Value of Carcinoembryonic Antigen (CEA), AFP, CA19-9 and CA125 for Patients with Colorectal Cancer with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy. Y.R. HUO, Y. HUANG, W. LIAUW, J. ZHAO, D.L. MORRIS ( <i>Sydney, NSW, Australia</i> ).....	1041
Prognostic Value of Anti-Müllerian Hormone and Inhibin B in Patients with Premenopausal Hormone Receptor-positive Breast Cancer. H.-A. KIM, M.-K. SEONG, J.H. KIM, Y.G. KIM, H.S. CHOI, J.-S. KIM, I.-C. PARK, H.-O. JIN, J.K. LEE, W.C. NOH ( <i>Seoul, Republic of Korea</i> ) .....	1051
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma? M. MIAN, M. TINELLI, E. DE MARCH, G. TURRI, V. MENEGHINI, N. PES COSTA, T. BERNO, A. MARABESE, P. MONDELLO, F. PATRIARCA, G. PIZZOLO, G. SEMENZATO, S. CORTELAZZO, R. ZAMBELLO ( <i>Bolzano; Verona; Padua; Messina; Udine; Bergamo, Italy; Innsbruck, Austria</i> ).....	1059
Computed Tomographic Features of Malignant Peritoneal Mesothelioma. K. KATO, K. GEMBA, N. FUJIMOTO, K. AOE, Y. TAKESHIMA, K. INAI, T. KISHIMOTO ( <i>Okayama; Ube; Hiroshima, Japan</i> ).....	1067
A Survival Score for Patients Receiving Stereotactic Radiosurgery Alone for Brain Metastases from Breast Cancer. D. RADES, L. DZIGGEL, S. JANSSEN, O. BLANCK, D. HORNUNG, S.E. SCHILD ( <i>Lübeck; Hannover; Güstrow; Hamburg, Germany; Scottsdale, AZ, USA</i> ).....	1073
The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy. M. SVATON, O. FIALA, M. PESEK, Z. BORTLICEK, M. MINARIK, L. BENESOVA, O. TOPOLCAN ( <i>Prague; Brno, Czech Republic</i> ) .....	1077

NDRG2 and NDRG4 Expression Is Altered in Glioblastoma and Influences Survival in Patients with <i>MGMT</i> -methylated Tumors. M.A. KOŁODZIEJ, C. WEISCHER, M.H.T. REINGES, E. UHL, M.A. WEIGAND, F.P. SCHWARM, A. SCHÄNZER, T. ACKER, K. QUINT, F. UHLE, M. STEIN ( <i>Giessen; Heidelberg; Erlangen, Germany</i> ) .....	887
Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma. J. PROSKE, L. WALTER, E. BUMES, M. HUTTERER, A. VOLLMANN-ZWERENZ, I.Y. EYÜPOGLU, N.E. SAVASKAN, C. SELIGER, P. HAU, M. UHL ( <i>Regensburg; Erlangen, Germany</i> ) .....	899
Novel Hyaluronan Formulation Enhances the Efficacy of Boron Neutron Capture Therapy for Murine Mesothelioma. M. SASAI, H. NAKAMURA, N. SOUGAWA, Y. SAKURAI, M. SUZUKI, C.M. LEE ( <i>Osaka; Tokyo, Japan</i> ) .....	907
Inhibition of Survivin Is Associated with Zoledronic Acid-induced Apoptosis of Prostate Cancer Cells. M. FRAGNI, S.A. BONINI, A. STABILE, S. BODEI, L. CRISTINELLI, C. SIMEONE, D. ZANI, P.F. SPANO, A. BERRUTI, M. MEMO, S. SIGALA ( <i>Brescia; Milan, Italy</i> ) .....	913
Expression Pattern of CDX2, Estrogen and Progesterone Receptors in Primary Gastroenteropancreatic Neuroendocrine Tumors and Metastases. N. ZIMMERMANN, P. LAZAR-KARSTEN, T. KECK, F. BILLMANN, S. SCHMID, G. BRABANT, C. THORNS ( <i>Lübeck, Germany</i> ) .....	921
Ginsenoside 20(S)-Protopanaxadiol Suppresses Viability of Human Glioblastoma Cells <i>via</i> Down-regulation of Cell Adhesion Proteins and Cell-cycle Arrest. C. WANDERI, E. KIM, S. CHANG, C. CHOI, K. CHOI ( <i>Daejeon, Republic of Korea</i> ) .....	925
<i>Clinical Studies</i>	
Split-Course Accelerated Hypofractionated Radiotherapy (SCAHRT): A Safe and Effective Option for Head and Neck Cancer in the Elderly or Infirm. T.J. BLEDSOE, A.R. NOBLE, C.A. REDDY, B.B. BURKEY, J.F. GRESKOVICH, T. NWIZU, D.J. ADELSTEIN, J.P. SAXTON, S.A. KOYFMAN ( <i>New Haven, CT; Cleveland, OH, USA</i> ) .....	933
The WHO Grade I Collagen-forming Meningioma Produces Angiogenic Substances. A New Meningioma Entity. J. HAYBAECK, E. SMOLLE, B. SCHÖKLER, R. KLEINERT ( <i>Graz, Austria</i> ) .....	941
Expression of $\gamma$ -Synuclein in Bladder Carcinoma: A Possible Marker for Prognosis. Z. CHEN, Z. JI, Q. WANG, B. SHI, C. SHOU, C. LIU, H. FAN, H. LI, K.T. DAVIDSON, M.R. WAKEFIELD, T.W. BALL, Y. FANG ( <i>Beijing, PR China; Des Moines, IA; Columbia, MO, USA</i> ) .....	951
A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women. P. LEANDERSSON, G. KALAPOTHARAKOS, E. HENIC, H. BORGFELDT, M. PETZOLD, G. HØYER-HANSEN, C. BORGFELDT ( <i>Lund; Gothenburg, Sweden; Copenhagen, Denmark</i> ) .....	957
First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study. A. SCHNEEWEISS, F. FÖRSTER, H. TESCH, B. AKTAS, O. GLUZ, M. GEBERTH, M.M. HERTZ-EICHENRODE, W. SCHÖNEGG, C. SCHUMACHER, A. KUTSCHEIDT, C. KIEWITZ, S. KLAWITTER, M. SCHMIDT ( <i>Heidelberg; Chemnitz; Frankfurt/Main; Essen; Mönchengladbach; Mannheim; Remscheid; Berlin; Köln; Langenfeld; Grenzach; Mainz, Germany</i> ) .....	967
Treatment of Oncological Post-surgical Wound Dehiscence with Autologous Skin Micrografts. E. BAGLIONI, L. TROVATO, M. MARCARELLI, A. FRENELLO, M.A. BOCCHIOTTI ( <i>Turin; Moncalieri, Italy</i> ) .....	975
Extent of Salvage Neck Dissection in Advanced Oro- and Hypopharyngeal Cancer. S. HOCH, F. BOHNE, N. FRANKE, T. WILHELM, A. TEYMOORTASH ( <i>Marburg; Borna, Germany</i> ) .....	981